Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Files An 8-K Results of Operations and Financial Condition
Item2.02.
|
Results of Operations and Financial Condition |
On May4, 2017, Achillion Pharmaceuticals, Inc. (the Company)
announced its financial results for the fiscal quarter ended
March31, 2017. The full text of the press release issued in
connection with the announcement is furnished as Exhibit 99.1 to
this Current Report on Form8-K.
The information in
this Form 8-K (including Exhibit 99.1) shall not be deemed filed
for purposes of Section18 of the Securities Exchange Act of 1934
(the Exchange Act) or otherwise subject to the liabilities of
that section, nor shall it be deemed incorporated by reference in
any filing under the Securities Act of 1933 or the Exchange Act,
except as expressly set forth by specific reference in such a
filing.
| Item9.01. | Financial Statements and Exhibits |
| (d) | Exhibits |
The following
exhibit relating to Item 2.02 shall be deemed to be furnished,
and not filed:
| 99.1 | Press Release dated May4, 2017 |
About Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)
Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system. The complement system is part of the body’s immune system. The Company has initiated a first-in-human Phase I clinical trial for its first complement factor D inhibitor, ACH-4471, to assess safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD. The Company has developed a portfolio of drug candidates, including odalasvir, ACH-3422 and sovaprevir. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Recent Trading Information
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) closed its last trading session down -0.08 at 3.44 with 838,499 shares trading hands.
